Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)

Abbott1 site in 1 country1,938 target enrollmentAugust 2004

ConditionsRheumatoid Arthritis

Drugsadalimumab

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Rheumatoid Arthritis
Sponsor: Abbott
Enrollment: 1938
Locations: 1
Primary Endpoint: Patient reported outcomes, clinical response indicators.
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment

Registry

clinicaltrials.gov

Start Date

August 2004

End Date

TBD

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Abbott

Eligibility Criteria

Inclusion Criteria

•Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
•Subject, based on assessment of investigator, meets the definition of active RA

Exclusion Criteria

•Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
•Female subject who is pregnant or breast-feeding or considering becoming pregnant

Outcomes

Primary Outcomes

Patient reported outcomes, clinical response indicators.

Secondary Outcomes

Subject reported assessments of disease activity, physician reported assessments of disease activity, safety parameters, clinical response indicators.